SecBot SecBot

KRYS

Krystal Biotech, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001711279 Biotech & Drug Discovery
$305.23 −0.45 (−0.15%)
Nov 13 4:00 PM ET · prev $305.68
Market cap
$9.1B
Mid cap
Consensus
Buy
90% Buy or better · 20 analysts
Median target
$380.00
+24% · range $284.00–474.00
1 year
+46.6%
from $208.25 · Nov 17
30 days
−4.7%
from $320.25
52-week range
$204.10–378.15
−19% from high · low Nov 19
Avg volume 20D
315.9K
Nov 2 spike 1.20M
Short interest
3.04M
≈10.3% of shares · +3.7%
Days to cover
12.2
at average volume
Insider net
−$26.5M
0 buyers · 4 sellers · since Jun 25
New fund stakes
3
Q3 2026 13F · 1 exit
Filing reports
18
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 2 bearish · 4 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $26.5M.

  • InstitutionsBULLISH

    Q3 2026: 44 added (3 new), 20 trimmed or exited. Largest new: Clearbridge Investments $12.5M, Quadrature Capital $10.8M.

  • AnalystsBULLISH

    18 of 20 rate it Buy or better. Median target $380.00 (+24%).

  • EstimatesRISING

    Current-quarter EPS estimate $2.149 → $2.221 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.7% to 3.04M shares. 12.2 days to cover, ≈10.3% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 4.

Who's buying

13F· Q3 2026
3
new positions
1
exit
$23.3M
in new stakes · top 2 shown
FundMoveSharesValue
FRANKLIN TEMPLETON INCADD370,951$115.3M
WESTFIELD CAPITAL MANAGEMENT CO LPADD171,170$56.9M
JPMORGAN CHASE & COADD167,450$56.6M
MORGAN STANLEYTRIM160,178$53.3M
PRINCIPAL FINANCIAL GROUP INCTRIM125,811$41.8M
UBS Group AGTRIM105,900$35.2M
RHUMBLINE ADVISERSADD79,635$26.5M
CONGRESS ASSET MANAGEMENT COADD54,083$18.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 90% rate it Buy or better
Strong Buy7Buy11Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +24%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 3, 2026Citigroup
MAINTAIN
MAINTAINBuy
Nov 3, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Nov 3, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 21, 2026B of A Securities
MAINTAIN
MAINTAINBuy
Aug 14, 2026RBC Capital
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$26.5M
sold · 4 insiders
DateInsiderTypeValue
Nov 12, 2026
ROSSI DINO A
Director
Nov 12, 2026
GIFT3,500 sh
Sep 14, 2026
Gangolli Julian S
Director
Sep 14, 2026
AWARD1,187 sh
Sep 14, 2026
Gangolli Julian S
Director
Sep 14, 2026
AWARD471 sh
Sep 14, 2026
JANNEY DANIEL
Director
Sep 14, 2026
AWARD1,187 sh
Sep 14, 2026
Mason Christopher
Director
Sep 14, 2026
AWARD1,187 sh
Sep 14, 2026
JANNEY DANIEL
Director
Sep 14, 2026
AWARD471 sh
Sep 14, 2026
Mason Christopher
Director
Sep 14, 2026
AWARD471 sh
Sep 14, 2026
Sutherland Everett Rand
Director
Sep 14, 2026
AWARD471 sh

Earnings setup

Estimates
$2.22
EPS estimate, this quarter
+3%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$2.22$1.79–$4.06-0.7%$134.5M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 2, 2026
Earnings
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch
Nov 2, 2026
Earnings result
KRYS Q3 2026 Earnings: EPS $2.05 (+13.5% vs est)
Oct 22, 2026
Earnings
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third…
Oct 15, 2026
Press release
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was…
Sep 3, 2026
Press release
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will…

Short side

FINRA· Oct 30, 2026
3,044,878
shares short
+3.7%
vs prior settlement
12.2
days to cover
≈10.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 Insider
ROSSI DINO A gifted 3,500 shares
Director
Nov 2, 2026 SEC
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY, above the $126.5M consensus. GAAP diluted EPS…
8-K · Impact 6/10
Nov 2, 2026 SEC
Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY and above the $126.5M consensus. GAAP diluted…
PRESS-RELEASE · Impact 6/10
Nov 2, 2026 Earnings
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch
Oct 30, 2026 SEC
Vanguard Portfolio Management LLC filed an amended Schedule 13G for Krystal Biotech, reporting beneficial ownership of…
SC 13G/A · Impact 5/10
Sep 30, 2026 Inst.
FRANKLIN TEMPLETON INC · ADD
370,951 shares ($115.3M)
Sep 30, 2026 Inst.
WESTFIELD CAPITAL MANAGEMENT CO · ADD
171,170 shares ($56.9M)
Sep 14, 2026 Insider
Gangolli Julian S was granted 1,187 shares
Director
Reddit
Recent posts
All social signals and their track records

SecBot reports

18 filings · 6 bullish · 2 bearish · 10 neutral
All KRYS filing & press-release reports (18)